BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--$bgne #beigene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),…
4 years ago
Genius Group Announced the Initial Results of Its Shares Market Activity Investigation
SINGAPORE--(BUSINESS WIRE)--$GNS #GNS--Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading…
4 years ago
Hong Kong Baptist University-led research discovers new therapeutic target for irritable bowel syndrome
HONG KONG SAR - Media OutReach - 4 January 2023 - A research study led…
4 years ago
Radware Schedules Conference Call for Its Fourth Quarter and Full Year 2022 Earnings
TEL AVIV, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Radware® (NASDAQ: RDWR), a leading provider…
4 years ago
Piedmont Lithium Expands Board of Directors
Christina Alvord and Michael Bless appointed to newly created directorships BELMONT, N.C.--(BUSINESS WIRE)--$PLL #EV--Piedmont Lithium…
4 years ago
Mercedes-Benz Energy and Lohum Advancing Battery Sustainability Through Multi-Year 2nd Life Partnership
NEW DELHI--(BUSINESS WIRE)--#BatterySupplyChain--Mercedes-Benz Energy and Lohum are pleased to announce a strategic partnership through a…
4 years ago
China Manganese Ore Import Industry Report 2022: Manganese Ore, Pyrolusite, Psilomelane, Manganite, Black Manganese Ore Import Analysis 2018-2022, Major Import Sources and Outlook 2023-2032 – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Research Report on China's Manganese Ore Import 2023-2032" report has been added to…
4 years ago
16,384 LEDs to revolutionize automotive lighting: Nichia and Infineon launch industry’s first high-definition micro-LED matrix solution
MUNICH, GERMANY and TOKUSHIMA, JAPAN - Media OutReach - 4 January 2023 - Automotive LED…
4 years ago
Hong Hong Baptist University-led research discovers new therapeutic target for irritable bowel syndrome
HONG KONG SAR - Media OutReach - 4 January 2023 - A research study led…
4 years ago
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Submission based on DESTINY-Lung02 and DESTINY-Lung01 phase 2 trial results which showed Daiichi Sankyo and…
4 years ago